Early clinical data on psilocybin in anorexia point Compass to potential new opportunitynews2022-05-03T12:34:54+00:00May 3rd, 2022|FierceBiotech|
Dianthus to follow ‘north star’ on mission to reduce autoimmune injections with $100M fundingnews2022-05-03T12:19:22+00:00May 3rd, 2022|FierceBiotech|
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rivalnews2022-05-03T07:10:53+00:00May 3rd, 2022|FierceBiotech|
As expected, FDA spikes down Axsome migraine med, but issues are ‘addressable’news2022-05-02T20:25:51+00:00May 2nd, 2022|FierceBiotech|
All Takeda wants for its billion-dollar gene therapy spending spree is functional curesnews2022-05-02T19:36:34+00:00May 2nd, 2022|FierceBiotech|
Biogen takes another dip into Scribe gene therapy collab with another disease targetnews2022-05-02T17:30:01+00:00May 2nd, 2022|FierceBiotech|
Patient Square Capital invests $300M to support ‘golden age of therapeutics’ with Enavate Sciencesnews2022-05-02T15:52:57+00:00May 2nd, 2022|FierceBiotech|
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy studynews2022-05-02T14:23:05+00:00May 2nd, 2022|FierceBiotech|
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDAnews2022-05-02T14:16:24+00:00May 2nd, 2022|FierceBiotech|
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDAnews2022-05-02T14:16:24+00:00May 2nd, 2022|FierceBiotech|
